DNA Repair Defects in Cancer and Therapeutic Opportunities

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2022 Mar 23

PMID 35318271

Authors

Jessica L Hopkins

Li Lan

Lee Zou

Affiliations

Soon will be listed here.

Abstract

DNA repair and DNA damage signaling pathways are critical for the maintenance of genomic stability. Defects of DNA repair and damage signaling contribute to tumorigenesis, but also render cancer cells vulnerable to DNA damage and reliant on remaining repair and signaling activities. Here, we review the major classes of DNA repair and damage signaling defects in cancer, the genomic instability that they give rise to, and therapeutic strategies to exploit the resulting vulnerabilities. Furthermore, we discuss the impacts of DNA repair defects on both targeted therapy and immunotherapy, and highlight emerging principles for targeting DNA repair defects in cancer therapy.

Citing Articles

Overview of Wnt/β-Catenin Pathway and DNA Damage/Repair in Cancer.

Nadin S, Cuello-Carrion F, Cayado-Gutierrez N, Fanelli M Biology (Basel). 2025; 14(2).

PMID: 40001953 PMC: 11851563. DOI: 10.3390/biology14020185.

Review: performance of jujube and its extracts in cancer: therapeutic, toxicity-reducing and potentiating effects.

Gou B, Chen G, Huang S, Ning N, Gu Q, Duan S Front Oncol. 2025; 15:1489974.

PMID: 39944835 PMC: 11814214. DOI: 10.3389/fonc.2025.1489974.

Bee Pollen as a Source of Biopharmaceuticals for Neurodegeneration and Cancer Research: A Scoping Review and Translational Prospects.

Kacemi R, Campos M Molecules. 2025; 29(24).

PMID: 39769981 PMC: 11677910. DOI: 10.3390/molecules29245893.

A goldilocks computational protocol for inhibitor discovery targeting DNA damage responses including replication-repair functions.

Moiani D, Tainer J Front Mol Biosci. 2024; 11:1442267.

PMID: 39669672 PMC: 11635304. DOI: 10.3389/fmolb.2024.1442267.

Systematic identification of pathogenic variants of non-small cell lung cancer in the promoters of DNA-damage repair genes.

An M, Chen C, Xiang J, Li Y, Qiu P, Tang Y EBioMedicine. 2024; 110:105480.

PMID: 39631147 PMC: 11663791. DOI: 10.1016/j.ebiom.2024.105480.

References

Suszynska M, Ratajska M, Kozlowski P . BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res. 2020; 13(1):50. PMC: 7196220. DOI: 10.1186/s13048-020-00654-3. View

Yap T, OCarrigan B, Penney M, Lim J, Brown J, De Miguel Luken M . Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020; 38(27):3195-3204. PMC: 7499606. DOI: 10.1200/JCO.19.02404. View

Wu Z, Shi Y, Tibbetts R, Miyamoto S . Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 2006; 311(5764):1141-6. DOI: 10.1126/science.1121513. View

Oestergaard V, Langevin F, Kuiken H, Pace P, Niedzwiedz W, Simpson L . Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell. 2007; 28(5):798-809. PMC: 2148256. DOI: 10.1016/j.molcel.2007.09.020. View

Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

Tkac J, Xu G, Adhikary H, Young J, Gallo D, Escribano-Diaz C . HELB Is a Feedback Inhibitor of DNA End Resection. Mol Cell. 2016; 61(3):405-418. DOI: 10.1016/j.molcel.2015.12.013. View

Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang J, Wu-Baer F . REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. Mol Cell. 2021; 81(19):4008-4025.e7. PMC: 8500949. DOI: 10.1016/j.molcel.2021.08.016. View

Shivji M, Renaudin X, Williams C, Venkitaraman A . BRCA2 Regulates Transcription Elongation by RNA Polymerase II to Prevent R-Loop Accumulation. Cell Rep. 2018; 22(4):1031-1039. PMC: 5846855. DOI: 10.1016/j.celrep.2017.12.086. View

Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K . ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018; 128(9):3926-3940. PMC: 6118586. DOI: 10.1172/JCI96519. View

10.

Williamson C, Miller R, Pemberton H, Jones S, Campbell J, Konde A . ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016; 7:13837. PMC: 5159945. DOI: 10.1038/ncomms13837. View

11.

Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M . Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol. 2013; 20(3):347-54. PMC: 3897332. DOI: 10.1038/nsmb.2501. View

12.

Lynch H, de la Chapelle A . Hereditary colorectal cancer. N Engl J Med. 2003; 348(10):919-32. DOI: 10.1056/NEJMra012242. View

13.

Simoneau A, Xiong R, Zou L . The cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells. Genes Dev. 2021; 35(17-18):1271-1289. PMC: 8415318. DOI: 10.1101/gad.348479.121. View

14.

Rogers R, Walton M, Cherry D, Collins I, Clarke P, Garrett M . CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. Cancer Res. 2020; 80(8):1735-1747. PMC: 7611445. DOI: 10.1158/0008-5472.CAN-19-1372. View

15.

Pettitt S, Rehman F, Bajrami I, Brough R, Wallberg F, Kozarewa I . A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520. PMC: 3636235. DOI: 10.1371/journal.pone.0061520. View

16.

Pilger D, Seymour L, Jackson S . Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes Dev. 2021; 35(9-10):602-618. PMC: 8091970. DOI: 10.1101/gad.348314.121. View

17.

Chen L, Chen J, Huang Y, Gu Y, Qiu J, Qian H . The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Mol Cell. 2018; 69(3):412-425.e6. PMC: 5957072. DOI: 10.1016/j.molcel.2017.12.029. View

18.

Vikas P, Borcherding N, Chennamadhavuni A, Garje R . Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Front Oncol. 2020; 10:570. PMC: 7228136. DOI: 10.3389/fonc.2020.00570. View

19.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

20.

Buisson R, Lawrence M, Benes C, Zou L . APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. Cancer Res. 2017; 77(17):4567-4578. PMC: 5609510. DOI: 10.1158/0008-5472.CAN-16-3389. View